Zobrazeno 1 - 10
of 198
pro vyhledávání: ''
Autor:
Takahiko Nakamura, Kenjiro Tsuruoka, Kiyoe Kanaoka, Yosuke Tamura, Yasuhito Fujisaka, Soichiro Ikeda, Tomoya Funamoto, Masafumi Imanishi, Isao Goto, Akihisa Imagawa, Hiroyuki Tsuji, Sho Mitsuya, Ninso Matsunaga
Publikováno v:
Anticancer Research. 41:5137-5145
BACKGROUND For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to prolong survival. To date, a comparison of second- and third-generation EGFR-T
Autor:
Pedro Rocha, Dzifa Y. Douse, Lixia Diao, Humam Kadara, Jianjun Zhang, Debora A. Ledesma, Jose Luis Solorzano, John V. Heymach, Ruth Salazar, Luisa M. Solis, Neda Kalhor, Barbara Mino, J. Jack Lee, Don L. Gibbons, Cesar A. Moran, David C. Rice, Carmen Behrens, Pamela Villalobos, Ara A. Vaporciyan, Jiexin Zhang, Hitoshi Dejima, Annikka Weissferdt, Kyle G. Mitchell, Tina Cascone, Edwin Parra-Cuentas, Boris Sepesi, Xiuning Le, Ignacio I. Wistuba
Publikováno v:
Cancer Immunology, Immunotherapy
Introduction CD73 is a membrane-bound enzyme crucial in adenosine generation. The adenosinergic pathway plays a critical role in immunosuppression and in anti-tumor effects of immune checkpoint inhibitors (ICI). Here, we interrogated CD73 expression
Autor:
Satoshi Ikeda, Kentaro Tanaka, Masafumi Sata, Hiroshi Tanaka, Eiki Ichihara, Takeharu Yamanaka, Masaki Kanazu, Yuichi Takiguchi, Hiroaki Okamoto, Hidehito Horinouchi, Yasuhiro Goto, Koichi Hagiwara, Satoru Miura, Terufumi Kato
Publikováno v:
Clinical Lung Cancer. 21:e592-e596
We describe the treatment rationale and design of our randomized phase III study, the ACHILLES trial (Japan Registry of Clinical Trials: jRCTs031180175). The aim of this study is to investigate the superiority of afatinib over chemotherapy as first-l
Autor:
Koji Arihiro, Morihito Okada, Yoshinori Handa, Yoshihiro Miyata, Yasuhiro Tsutani, Yuichiro Kai, Yukio Takeshima, Takahiro Mimae, Noriyuki Shiroma
Publikováno v:
Clinical Lung Cancer. 21:e302-e314
Background The programmed death 1/programmed death-ligand 1 (PD-L1) pathway reportedly is as an important factor determining effects of immunotherapy; however, its prognostic impact is controversial, and its association with the surrounding immune mi
Autor:
Mario Miccoli, Iacopo Petrini, Marzia Del Re, Antonio Chella, Marina Chiara Garassino, Giulia Gianfilippo, Daniele Pozzessere, Francesca Mazzoni, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Romano Danesi, Simona Valleggi
Publikováno v:
Clinical Lung Cancer. 21:232-237
Background Insights into the mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further patient management, including the choice of second-line treatment. The E
Autor:
Nabil Chehab, Melissa Pavilack, Janakiraman Subramanian, Jennifer W. Wu, Mei Sheng Duh, François Laliberté, Anne C. Chiang, Ancilla W. Fernandes
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
BMC Cancer
BMC Cancer
Background The objective of this study was to investigate real-world EGFR mutation testing in patients with metastatic non-small cell lung cancer (NSCLC) upon progression on first−/second-generation epidermal growth factor receptor (EGFR)-tyrosine
Autor:
Hui Zhang, Xiao Yunpeng, Jian Zhang, Hua-Xin Liao, Jun Jiang, Qian-Ting Wang, Li Junqi, You-Wen He, Xiaohui Yuan, Shiyou Li, Zhe Li, Yu-Ying Fan, Sheng-Nan Sun, Ming Zeng, Ru-Jin Han, Bin-Bin Zhao, Ying Nie, Tao Lin
Publikováno v:
Cancer Immunology, Immunotherapy. 69:1375-1387
Tumor-associated antigens (TAAs) have been tested in various clinical trials in cancer treatment but the patterns of specific T cell response to personalized TAA immunization remains to be fully understood. We report antigen-specific T cell responses
Autor:
Xue-Ning Yang, Xu-Chao Zhang, Yu Chen, Wen-Qing Yan, Wei-Bang Guo, Yi-Long Wu, Zhi Xie, Hui-Bo Feng, Kai Yin, Dan-Xia Lu, Zhi-Yi Lv, Lin-Lin Li
Publikováno v:
Thoracic Cancer, Vol 11, Iss 2, Pp 346-352 (2020)
Thoracic Cancer
Thoracic Cancer
Background Primary pulmonary lymphoepithelioma‐like carcinoma (PLELC) is a rare and unique subtype of lung cancer. However, the prevalence of driver alterations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kina
Autor:
Raffaele Giusti, Giorgia Guaitoli, Mario Occhipinti, Diego Cortinovis, Ornella Cantale, Luca Cantini, Cinzia Baldessari, Alessio Cortellini, Francesco Grossi, Linda Pettoruti, Vincenzo Sforza, Giovanni Mansueto, Francesco Passiglia, Francesca Mazzoni, Lorenza Landi, Alain Gelibter, Melissa Bersanelli, Daniele Santini, Paolo Marchetti, Alessandro Morabito, Alessandro Leonetti, Marianna Tudini, Serena Ricciardi, Fabrizio Citarella, Ettore D'Argento, Francesca Rastelli, Matteo Santoni, Vincenzo Di Noia, Giampiero Porzio, Robert A. Belderbos, Claudia Proto, Simona Scodes, Marianna Macerelli, Marco Filetti, Joachim G.J.V. Aerts, Diego Signorelli, Luigi Della Gravara, Carlo Genova, Danilo Rocco, Lorenzo Antonuzzo, Alessandro Tuzi, Cristina Cecchi, Luca Sala, Corrado Ficorella, Marco De Filippis, Giuseppe Luigi Banna, Alessandro Inno, Mariangela Torniai, Pamela Pizzutilo, Emilio Bria, Maria Giovanna Dal Bello, Domenico Galetta, Federico Cappuzzo, Federica Bertolini, Rossana Berardi, Maria Rita Migliorino, Miriam Grazia Ferrara, Clelia Donisi, Rita Chiari, Alessandro De Toma, Olga Nigro, Michele Ghidini, Annamaria Catino, Alfredo Addeo, Federica Zoratto, Alessandro Follador, Pietro Di Marino, Alex Friedlaender, Marco Russano, Biagio Ricciuti, Katia Cannita
Publikováno v:
Clinical Lung Cancer, 21(6), 498-508.e2. Elsevier
The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non-small-cell lung
Autor:
Masayuki Takeda, Kaoru Tanaka, Kimio Yonesaka, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Takayuki Takahama, Ryoji Kato, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Lung Cancer. 139:28-34
Objectives The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between